Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies to cure a broad range of genetic diseases, shared new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The company presented data demonstrating that its next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, Tevard presented data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model as well as functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
According to the announcement, Tevard's next-generation suppressor tRNAs achieve approximately 100% restoration of full-length dystrophin in DMD models and deliver durable full-length titin rescue in TTN-related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. The presented programs highlight the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.
The findings underscore the potential of Tevard's suppressor tRNA platform to address diseases caused by premature termination codons, which are responsible for a range of genetic disorders. By restoring endogenous, full-length protein expression, the platform offers a novel therapeutic approach for conditions such as DMD and DCM-TTNtv, which currently have limited treatment options. The data presented at ASGCT 2026 represent a significant step forward in the development of tRNA-based therapies for genetic diseases.
For more information about Tevard Biosciences and its programs, visit www.tevard.com.
